Brief: FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July 9
10/07/2026 13:16
BRIEF-FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July 9 July 10 (Reuters) - FDA:
FDA: ON JULY 9, FDA APPROVES ISATUXIMAB-IRFC FOR SUBCUTANEOUS INJECTION FOR MULTIPLE MYELOMA INDICATIONS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sanofi SA
See all newsEdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: AJ Bell, CMC Markets, Nestle